ID   MTA-13
AC   CVCL_B7N4
DR   Wikidata; Q112930130
RX   PubMed=12663051;
CC   Selected for resistance to: ChEBI; CHEBI:63616; Pemetrexed (Alimta; LY231514).
CC   Transformant: ChEBI; CHEBI:34342; 3-methylcholanthrene (3-MC; 20-methylcholanthrene; 20-MC; MCA).
CC   Transformant: ChEBI; CHEBI:23994; Ethyl methanesulfonate (Methylsulfonic acid ethyl ester; MSEE).
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
CC   Cell type: T-cell; CL=CL_0000084.
CC   Breed/subspecies: DBA/2.
DI   NCIt; C21604; Mouse leukemia
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_0382 ! L1210
SX   Female
AG   8M
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=12663051; DOI=10.1016/s0006-2952(03)00007-8;
RA   Wang Y.-H., Zhao R.-B., Goldman I.D.;
RT   "Decreased expression of the reduced folate carrier and
RT   folypolyglutamate synthetase is the basis for acquired resistance to
RT   the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell
RT   line.";
RL   Biochem. Pharmacol. 65:1163-1170(2003).
//